# Safety, Tolerability and Preliminary Efficacy of IBI363 in Subjects With Advanced Solid Tumors or Lymphoma

> **NCT05460767** · PHASE1 · UNKNOWN · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 260 (estimated)

## Conditions studied

- Solid Tumors or Lymphoma

## Interventions

- **BIOLOGICAL:** IBI363

## Key facts

- **NCT ID:** NCT05460767
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-31
- **Primary completion:** 2024-03-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 260 (ESTIMATED)
- **Last updated:** 2023-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05460767

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05460767, "Safety, Tolerability and Preliminary Efficacy of IBI363 in Subjects With Advanced Solid Tumors or Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05460767. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*